Top Markets
Coin of the day
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
株式のランク #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
株価
$0.00023723
最終同期: 2024-08-26
時価総額
$1.41K
変化(1日)
111.67%
変化(1年)
0.00%
FR
取引 Pharnext S.A. (ALPHA)

カテゴリー

Pharnext S.A.(ALPHA)のP/S比率
August 2026 時点のP/S比率 TTM: 0.12
Pharnext S.A. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0.12 です。2022 年末時点でのP/S比率は 17.807T でした。
Pharnext S.A. の P/S 比率の履歴(2012 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 0.12 -99.84%
2023 73.60 -100.00%
2022 17.807T -99.54%
2021 3.91Qa -97.44%
2020 152.45Qa 270.01%
2019 41.20Qa 1,356.30%
2018 2.83Qa -40.90%
2017 4.79Qa 24.33%
2016 3.85Qa -46.55%
2015 7.20Qa 4.78%
2014 6.87Qa -4.45%
2013 7.19Qa 0.00%
2012 0.00 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差
9.88 8,203.19%
US
10.30 8,557.98%
NL
- -
CH
4.98 4,084.29%
BE
- -
KR